Every 8-K that Viking Therapeutics, Inc (VKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VKTX filings page.
Viking Therapeutics, Inc. reported third-quarter 2026 financial results, including a net loss of $183.2 million, compared with $90.8 million a year earlier. Research and development expenses were $166.8 million and general and administrative expenses were $20.3 million, both higher than in the prior-year quarter. Cash, cash equivalents and short-term investments totaled $960 million at September 30, 2026, versus $706 million at December 31, 2025. Concurrent public offerings of common stock and convertible senior notes in September generated approximately $575 million in gross proceeds.
The subcutaneous VANQUISH trials continued, and Viking initiated the oral SUNRISE Phase 3 trials for VK2735; VANQUISH completion is expected in 2027. VANQUISH tests weekly injections over 78 weeks, while SUNRISE tests daily tablets over 68 weeks. In Part 1 of a maintenance study, mean weight loss retained at Week 33 was 83%–97% with every-other-week dosing and 82%–90% with monthly dosing. Part 2 began, with results expected in 2027. Viking expected to complete VK3019’s Phase 1 single-ascending-dose study later in the quarter and initiate a 4-week multiple-ascending-dose study in the first quarter of 2027.
Viking Therapeutics, Inc. (VKTX) completed an equity offering and a convertible debt offering on September 25, 2026. The equity offering comprised 7,857,143 common shares at $35.00 per share, plus 1,178,571 additional shares under an option exercised in full; net proceeds were approximately $297.0 million. The debt offering comprised $225,000,000 aggregate principal amount of 2.00% convertible senior notes due 2032, plus $33,750,000 under an option exercised in full; net proceeds were approximately $250.8 million.
The notes are senior, unsecured obligations, pay interest semi-annually beginning April 15, 2027, and mature October 15, 2032 unless earlier repurchased, redeemed or converted. Their initial conversion rate is 19.7044 common shares per $1,000 principal amount, representing an initial conversion price of approximately $50.75 per share. Viking may settle conversions in cash, shares or a combination, at its election. The company intends to use net proceeds from both offerings for continued clinical development, advancement and commercialization of VK2735; clinical development and advancement of VK3019; and other research and development, working capital and general corporate purposes.
Viking Therapeutics, Inc. (VKTX) reported positive top-line results from a randomized, double-blind, placebo-controlled maintenance study of its dual GLP-1/GIP agonist VK2735 in adults with obesity. After a 21-week once-weekly induction phase, VK2735 produced mean weight loss of about 16–19% versus approximately 0% for placebo, with no plateau observed.
In the 12-week maintenance phase, subjects transitioning from weekly VK2735 to every-other-week dosing maintained up to 97% of prior weight loss, and those on monthly dosing maintained up to 90%, compared with 61% for placebo. An exploratory cohort continuing 17.5 mg weekly VK2735 achieved about 21.7% mean weight loss at Week 33 versus a 0.3% gain for placebo. Across maintenance regimens, rates of gastrointestinal adverse events and discontinuations were low and generally similar to placebo, which the company characterizes as an encouraging tolerability profile.
Viking Therapeutics reported second quarter 2026 results alongside an update on its obesity-focused pipeline. Research and development expense rose to $115.8 million and general and administrative expense to $16.9 million, leading to a net loss of $128.0 million, or $1.10 per share. For the first half of 2026, net loss was $286.3 million. Cash, cash equivalents and short-term investments were $502 million at June 30, 2026, compared with $706 million at December 31, 2025.
The company emphasized progress for dual GLP‑1/GIP agonist VK2735, with subcutaneous Phase 3 VANQUISH‑1 and ‑2 obesity trials fully enrolled at approximately 4,500 and 1,000 patients, respectively, and an oral Phase 3 program targeted to begin in 4Q26. A VK2735 maintenance-dosing study is expected to deliver data in 3Q26. Viking also initiated a Phase 1 trial of amylin receptor agonist VK3019 in obesity and strengthened leadership by appointing Hubert Chen, M.D., as chief medical officer and adding Dorothy Gemmell to the board.
Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of the 115,893,943 common shares outstanding as of March 20, 2026, 80,089,532 shares were represented, about 69.1% of shares entitled to vote, establishing a quorum.
Stockholders elected Class II directors J. Matthew Singleton and S. Kathryn Rouan, Ph.D., to serve until the 2029 annual meeting or until their successors are elected and qualified. They also ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement. These outcomes confirm continuity in Viking’s board composition, auditor relationship, and executive pay program.
Viking Therapeutics reported a larger first quarter 2026 loss as it ramps investment in its obesity pipeline. The company posted a net loss of $158.3 million, or $1.37 per share, compared with a net loss of $45.6 million, or $0.41 per share, a year earlier. Research and development expenses rose to $150.2 million from $41.4 million, while general and administrative costs were roughly flat at $14.0 million.
Viking ended March 31, 2026 with $603 million in cash, cash equivalents and short-term investments, down from $706 million at year-end 2025, supporting continued clinical work. Its Phase 3 VANQUISH trials of subcutaneous VK2735 for obesity are fully enrolled, with more than 4,500 patients in VANQUISH-1 and approximately 1,000 in VANQUISH-2. A Phase 3 trial of oral VK2735 in obesity is planned to start in the fourth quarter of 2026, a maintenance dosing study is ongoing with data expected in the third quarter of 2026, and an IND has been filed for amylin agonist VK3019, with a Phase 1 trial targeted for the second quarter of 2026.
Viking Therapeutics reported a much larger net loss for 2025 as it accelerated investment in its obesity pipeline, led by dual GLP‑1/GIP agonist VK2735. For 2025, the company recorded a net loss of $358.5 million, or $3.19 per share, versus a loss of $110.0 million, or $1.01 per share, in 2024. Research and development spending rose to $345.0 million from $101.6 million, reflecting extensive Phase 3 work on subcutaneous VK2735, positive Phase 2 oral VK2735 data, and broader pipeline progress. General and administrative costs were roughly flat at $48.4 million. As of December 31, 2025, Viking held $706 million in cash, cash equivalents and short‑term investments, which the company believes supports key upcoming milestones. Clinical highlights include ongoing Phase 3 VANQUISH trials for injectable VK2735 in obesity, plans to start Phase 3 for oral VK2735 in 3Q26, a fully enrolled VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an IND for a novel amylin agonist in 1Q26.
Viking Therapeutics (VKTX) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1. The company notes that the information under Item 2.02 is furnished, not filed, under the Exchange Act.
Viking Therapeutics, Inc. filed a current report to highlight that, on August 19, 2025, it issued a press release announcing top-line results from its Phase 2 clinical trial of the oral tablet formulation of VK2735. The company furnished this press release as Exhibit 99.1 and clarified that the information provided under the Regulation FD disclosure section is being furnished rather than filed for liability purposes under securities laws.